Actinogen Medical Ltd has released a press release.
ACW announces Phase 2 trial designs for AD & MDD
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
In the deck
Earlier from Actinogen Medical
- Actinogen trial results & strategic update presentation
- Actinogen prioritizes Alzheimers Disease & Depression
- Quarterly Activity Report & Appendix 4C
- ACW positive XanaMIA results webcast slide presentation
- ACW announces positive XanaMIA results for Xanamem
Later from Actinogen Medical
- Application for quotation of securities - ACW
- ACW CEO presentation to Spark Plus Aust Equities Day
- ACW Appendix 4E and 2022 Annual Report
- Actinogen FY22 Results - Accelerating Clinical Development
- ACW announces positive Alzheimers Disease clinical results
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical